One of the most relevant drugs in this class is blinatumomab, a BiTE that binds CD3 on the T cells and CD19 on the B-cell precursor blasts of acute lymphoblastic leukemia (ALL), that lead to prolonged overall survival in patients with ALL (65). Here, CD19 is linked to acute lymphoblastic leukemia.